Tiziana Life Sciences PLC - London-based biotechnology firm - Submits patent application for the potential use of nasally administered Foralumab for the treatment of Covid-19, either alone or in combination with other anti-viral drugs. Foralumab is a fully human anti-CD3 monoclonal antibody.
Notes that recent clinical studies suggest that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients at different stages of Covid-19 disease and reduce respiratory failure.
Current stock price: 268.00 pence
Year-to-date change: down almost seven-fold.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
